• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazo[1,5-a]pyrazines

Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate (CAS No. 1256633-28-9): A Versatile Scaffold in Modern Pharmaceutical Research

Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate (CAS No. 1256633-28-9) is a significant compound in the realm of pharmaceutical chemistry, characterized by its unique structural framework and multifaceted applications. This heterocyclic derivative, featuring a fused imidazo[1,5-a]pyrazine core with two chlorine substituents at the 5 and 8 positions and a carboxylate ester group at the 1 position, has garnered considerable attention due to its potential as a pharmacophore in drug discovery.

The molecular structure of Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate imparts distinct chemical properties that make it an attractive candidate for medicinal chemistry. The presence of chlorine atoms at specific positions enhances its reactivity and binding affinity, enabling it to interact with biological targets in diverse ways. The carboxylate ester functionality further expands its utility by allowing modifications through ester hydrolysis or amidation, facilitating the synthesis of more complex derivatives.

In recent years, there has been a surge in research focused on imidazo[1,5-a]pyrazine derivatives due to their demonstrated efficacy in various therapeutic areas. These compounds have shown promise as inhibitors of kinases, transcription factors, and other key enzymes involved in cancer progression. Specifically, derivatives of this scaffold have been investigated for their ability to modulate pathways such as the PI3K/Akt/mTOR axis and MAPK signaling, which are crucial in tumor growth and survival.

One of the most compelling aspects of Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate is its versatility as a starting material for further chemical exploration. Researchers have leveraged its scaffold to develop novel inhibitors targeting specific disease-related proteins. For instance, studies have demonstrated that structural analogs of this compound can inhibit the activity of Janus kinases (JAKs), which play a pivotal role in inflammatory responses and autoimmune diseases. The chlorine substituents at the 5 and 8 positions provide handles for further derivatization, allowing chemists to fine-tune the pharmacokinetic and pharmacodynamic properties of these molecules.

The carboxylate ester group attached to the imidazo[1,5-a]pyrazine core offers additional opportunities for chemical modification. This moiety can be readily converted into other functional groups such as amides or carboxylic acids through enzymatic or chemical hydrolysis. Such transformations have enabled the synthesis of prodrugs that release active species in vivo under specific physiological conditions. This approach not only enhances bioavailability but also allows for targeted delivery to sites of disease activity.

Recent advances in computational chemistry have further accelerated the development of novel derivatives based on Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate. Molecular docking studies have identified key interactions between this scaffold and target proteins, providing insights into how structural modifications can improve binding affinity and selectivity. These computational predictions have guided experimental efforts toward designing more potent and selective inhibitors with reduced off-target effects.

The pharmaceutical industry has also recognized the potential of this compound as a building block for drug candidates. Several companies are currently engaged in synthesizing and evaluating derivatives of Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate for various therapeutic indications. Early-phase clinical trials have shown encouraging results with some analogs demonstrating significant anti-proliferative effects in cancer cell lines while maintaining acceptable safety profiles. These findings underscore the importance of this scaffold in developing next-generation therapeutics.

The synthesis of Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate itself is another area of active research. Chemists have developed efficient synthetic routes that allow for scalable production without compromising purity or yield. These methods often involve multi-step organic transformations starting from readily available precursors such as anthranilic acid derivatives or halogenated imidazoles. The optimization of these synthetic pathways is crucial for ensuring cost-effective production and availability for further medicinal chemistry applications.

In conclusion, Ethyl 5,8-dichloroimidazo[1,5-a]pyrazine-1-carboxylate (CAS No. 1256633-28-9) represents a valuable asset in pharmaceutical research due to its unique structural features and broad applicability. Its role as a versatile scaffold for drug discovery continues to be explored across multiple therapeutic areas with promising results emerging from both preclinical studies and clinical trials. As our understanding of biological pathways grows more sophisticated so too does our ability to harness compounds like this one toward developing innovative treatments that address unmet medical needs.

• 134044-64-7(Imidazo[1,2-a]pyrimidine-2-carboxylic acid, 5-chloro-7-methyl-, ethyl ester)
• 86110-31-8(IMIDAZO[1,5-A]QUINOXALINE-3-CARBOXYLIC ACID, 1,4-DICHLORO-, ETHYL ESTER)
• 864438-72-2(7-Chloro-5-Methyl-iMidazo[1,2-a]pyriMidine-2-carboxylic acid ethyl ester)
• 86110-26-1(Ethyl 4-Chloroimidazo1,5-aquinoxaline-3-carboxylate)
• 1823584-33-3(5-chloroiMidazo[1,5-a]pyrazine-1-carboxylic acid)
• 90510-56-8(Imidazo[1,5-a]quinoxaline-3-carboxylic acid, 4-chloro-)
• 1160248-06-5(Ethyl 8-Chloroimidazo[1,5-a]pyrazine-1-carboxylate)
• 1377584-27-4(ethyl imidazo[1,5-a]pyrazine-1-carboxylate)
• 1250996-90-7(Ethyl 5-chloroimidazo[1,5-a]pyrazine-1-carboxylate)
• 885271-54-5(Ethyl 5-chloroimidazo[1,5-a]pyridine-1-carboxylate)